Ual Meeting Proceedings J Clin Oncol twenty five:18S, 2007 (abstr 4010) Nagrath S, Sequist LV, Maheswaran SD, et al: Isolation of rare circulating tumour cells in most cancers clients by microchip technologies. Character 450: 12351239, 2007 Johnston P, Mulligan K, Kay E, et al: A genetic signature of relapse in phase II colorectal cancer derived from formalin mounted paraffin 107452-89-1 MedChemExpress embedded (FFPE) tissue using a singular sickness certain colorectal array. 2006 ASCO Once-a-year Meeting Proceedings. J Clin Oncol 24:18S, 2006 (abstr 3519) Del Rio MF, Molina C, Bascoul-Mollevi V, et al: Gene expression signature in advanced colorectal cancer patients pick drugs and response to the utilization of leucovorin, fluorouracil, and irinotecan. J Clin Oncol twenty five:773 eighty,7.8.9.ten. Kim GP, Colangelo LH, Wieand HS, et al: Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a Countrywide Most cancers Institute-National Surgical Adjuvant Breast and Bowel Task Collaborative Study. J Clin Oncol 25:76772, 2007 eleven. Kim GP, Colangelo LH, Paik S, et al: Predictive benefit of microsatellite instability-high stays controversial. J Clin Oncol 25:4857 (author reply 48574858), 2007 12. Watanabe T, Wu TT, Catalano PJ, et al: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1196206, 2001 thirteen. Van Cutsem E, Nowacki M, Lang I, et al: Randomized phase III research of irinotecan and 5-FU/FA with or with no cetuximab in the first-line treatment of individuals with metastatic colorectal cancer (mCRC): The CRYSTAL trial. 2007 ASCO Annual Assembly Proceedings. J Clin Oncol 25:18S, 2007 (abstr 4000) fourteen. Eng C, Maurel J, Scheithauer W, et al: Affect on high quality of life of including cetuximab to irinotecan in individuals who have failed prior oxaliplatin-based treatment: The EPIC trial. 2007 ASCO Annual Conference Proceedings. J Clin Oncol twenty five:18S, 2007 (abstr 4003) 15. Moore MJ, da Cunha Santos G, Kamel-Reid S, et al: The connection of Kras mutations and EGFR gene duplicate 1373422-53-7 site amount to consequence in sufferers addressed with erlotinib on National Cancer Institute of Canada Clinical Trials Group trial examine PA.3. 2007 ASCO Once-a-year Assembly Proceedings. J Clin Oncol twenty five:18S, 2007 (abstr 4521) sixteen. Xiong HQ, Rosenberg A, LoBuglio A, et al: Cetuximab, a monoclonal antibody concentrating on the epidermal advancement aspect receptor, in combination with 1639895-85-4 Epigenetics gemcitabine for state-of-the-art pancreatic most cancers: a multicenter section II trial. J Clin Oncol 22:2610-2616, 2004 17. Kindler HL, Friberg G, Singh DA, et al: Period II demo of bevacizumab additionally gemcitabine in clients with highly developed pancreatic cancer. J Clin Oncol 23:8033040, 2005 eighteen. Philip PA, Benedetti J, Fenoglio-Preiser C, et al: Period III examine of gemcitabine [G] additionally cetuximab [C] compared to gemcitabine in sufferers [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 research. 2007 ASCO Once-a-year Assembly Proceedings. J Clin Oncol 25:18S, 2007 (abstr LBA4509) 19. Kindler HL, Niedzwiecki D, Hollis D, et al: A double-blind, placebo-controlled, randomized stage III trial of gemcitabine (G) in addition bevacizumab (B) compared to gemcitabine as well as placebo (P) in individuals (pts) with highly developed pancreatic most cancers (Personal computer): a preliminary evaluation of Most cancers and Leukemia Team B (CALGB). 2007 ASCO Yearly Assembly Proceedings J Clin Oncol, twenty five:18S, 2007 (abstr 4508) twenty. Burtness BA, Powell M, Berlin J, et al: Period II trial of irinotecan/docetaxel for advanced pancreatic most cancers with randomization concerning irinotecan/docetaxel and irinotecan/docetaxel furthermore C2.
